The staging value of sentinel lymph node biopsy for breast cancer: translating pathologic findings to clinical practice.

Axillary nodal status is an important prognostic factor in guiding locoregional and systemic treatment for breast cancer. Sentinel lymph node biopsy (SNB) has revolutionized axillary staging by replacing axillary lymph node dissection (ALND) in node-negative women. Even in select patients whose sentinel lymph nodes (SLNs) contain metastases, SNB alone has become an accepted method of managing the axilla. Identification of micrometastases through immunohistochemical analysis of SLNs that are tumorfree on hematoxylin and eosin staining (H&E) does not confer additional clinical benefit. The use of SNB after neoadjuvant chemotherapy (NAC) remains controversial. In addition to axillary nodal status, tumor biology plays an increasingly important role in guiding therapeutic decisions.

[1]  Tanya Hoskin,et al.  Nonsentinel node metastasis in breast cancer patients: assessment of an existing and a new predictive nomogram. , 2005, American journal of surgery.

[2]  B. Gusterson,et al.  Role of immunohistochemical detection of lymph-node metastases in management of breast cancer , 1999, The Lancet.

[3]  G Villa,et al.  Sentinel node biopsy compared with complete axillary dissection for staging early breast cancer with clinically negative lymph nodes: results of randomized trial. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  C. Lawton.  Effect of Occult Metastases on Survival in Node-Negative Breast Cancer , 2012 .

[5]  A E Giuliano,et al.  Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. , 1997, Annals of surgery.

[6]  A. Luini,et al.  Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. , 1999, Journal of the National Cancer Institute.

[7]  A. Giuliano,et al.  The Prognostic Significance of Micrometastases in Breast Cancer: A SEER Population-Based Analysis , 2007, Annals of Surgical Oncology.

[8]  A. Giuliano,et al.  Improved Axillary Staging of Breast Cancer with Sentinel Lymphadenectomy , 1995, Annals of surgery.

[9]  Mark C Kelley,et al.  Lymphatic mapping and sentinel lymphadenectomy for breast cancer. , 2004, American journal of surgery.

[10]  R. Orr,et al.  Molecular Detection of Micrometastatic Breast Cancer in Histopathology—Negative Axillary Lymph Nodes Fails to Predict Breast Cancer Recurrence: A Final Analysis of a Prospective Multi-Institutional Cohort Study , 2010, Annals of Surgical Oncology.

[11]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[12]  A. Luini,et al.  Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. , 2013, The Lancet. Oncology.

[13]  T. Julian,et al.  Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Nitti,et al.  A Randomized Clinical Trial on Sentinel Lymph Node Biopsy Versus Axillary Lymph Node Dissection in Breast Cancer: Results of the Sentinella/GIVOM Trial , 2008, Annals of surgery.

[15]  D. Weaver,et al.  Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma , 2000, Cancer.

[16]  R. Mansel,et al.  Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. , 2014, The Lancet. Oncology.

[17]  R. Simmons,et al.  Scientific Impact Recognition Award. Sentinel node staging for breast cancer: intraoperative molecular pathology overcomes conventional histologic sampling errors. , 2007, American Journal of Surgery.

[18]  V. Livolsi,et al.  Recommendations for Handling Radioactive Specimens Obtained by Sentinel Lymphadenectomy , 2000, The American journal of surgical pathology.

[19]  M. Somerfield,et al.  Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  H. Kuerer,et al.  Meta‐analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer , 2006, The British journal of surgery.

[21]  S. Mclaughlin,et al.  Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. , 2013, JAMA.

[22]  A. Luini,et al.  Sentinel Lymph Node Biopsy in Breast Cancer: Ten-Year Results of a Randomized Controlled Study , 2010, Annals of surgery.

[23]  J. Thigpen.  Comparison of Sentinel Lymph Node Biopsy Alone and Completion Axillary Lymph Node Dissection for Node-Positive Breast Cancer , 2010 .

[24]  A. Giuliano,et al.  Evaluation of the stage IB designation of the American Joint Committee on Cancer staging system in breast cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Ross,et al.  Incorporation of Sentinel Lymph Node Metastasis Size Into a Nomogram Predicting Nonsentinel Lymph Node Involvement in Breast Cancer Patients With a Positive Sentinel Lymph Node , 2012, Annals of surgery.

[26]  Scott M Berry,et al.  Novel intraoperative molecular test for sentinel lymph node metastases in patients with early-stage breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  A. Giuliano,et al.  Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. , 2011, JAMA.

[28]  A E Giuliano,et al.  Sentinel lymphadenectomy in breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  P. V. van Diest,et al.  Micrometastases or isolated tumor cells and the outcome of breast cancer. , 2009, The New England journal of medicine.

[30]  H. Cody,et al.  A Declining Rate of Completion Axillary Dissection in Sentinel Lymph Node-positive Breast Cancer Patients Is Associated With the Use of a Multivariate Nomogram , 2007, Annals of surgery.

[31]  M. Ross,et al.  Feasibility and Accuracy of Sentinel Lymph Node Biopsy After Preoperative Chemotherapy in Breast Cancer Patients With Documented Axillary Metastases , 2007, Cancer.

[32]  G. Gill,et al.  Sentinel-Lymph-Node-Based Management or Routine Axillary Clearance? One-Year Outcomes of Sentinel Node Biopsy Versus Axillary Clearance (SNAC): A Randomized Controlled Surgical Trial , 2009, Annals of Surgical Oncology.

[33]  Long-Term Follow-up Study of a Prospective Multicenter Sentinel Node Trial: Molecular Detection of Breast Cancer Sentinel Node Metastases , 2010, Annals of Surgical Oncology.

[34]  Hiram S. Cody,et al.  A Nomogram for Predicting the Likelihood of Additional Nodal Metastases in Breast Cancer Patients With a Positive Sentinel Node Biopsy , 2003, Annals of Surgical Oncology.

[35]  H. Kuerer,et al.  Trends in and Outcomes from Sentinel Lymph Node Biopsy (SLNB) Alone vs. SLNB with Axillary Lymph Node Dissection for Node-Positive Breast Cancer Patients: Experience from the SEER Database , 2010, Annals of Surgical Oncology.

[36]  T. Julian,et al.  Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. , 2007, The Lancet. Oncology.

[37]  A. Giuliano,et al.  Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. , 2011, JAMA.